Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its ...

Revvity, Inc. , today announced the launch of three Mimixtm reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting ...

EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS | Embrace the transformative power of multimodal ...

PDS Biotechnology ( ($PDSB) ) has shared an update. On June 2, 2025, PDS Biotechnology Corporation announced the publication of three Versamune® ...

HOUSTON, TX, USA and CHICAGO, IL, USA I May 29, 2025 I RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...

Data shows adding durvalumab (Imfinzi) to the standard chemotherapy combination known as FLOT before and after surgery kept ...

As shown in table 2, both OS and CBR values were in line or higher than those reported in the treatment arm of the ASCENT ...